Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
5(45%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
8
73%
Ph phase_4
1
9%

Phase Distribution

0

Early Stage

8

Mid Stage

1

Late Stage

Phase Distribution9 total trials
Phase 2Efficacy & side effects
8(88.9%)
Phase 4Post-market surveillance
1(11.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

5

trials recruiting

Total Trials

11

all time

Status Distribution
Active(8)
Completed(2)
Other(1)

Detailed Status

Recruiting4
Not yet recruiting3
Completed2
Active, not recruiting1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
5
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 28 (88.9%)
Phase 41 (11.1%)

Trials by Status

recruiting436%
not_yet_recruiting327%
active_not_recruiting19%
unknown19%
completed218%

Recent Activity

5 active trials
Showing 5 of 11
active_not_recruiting

Efficacy and Survival Analysis of Perioperative Treatment of Locally Advanced Gastric or Gastroesophageal Junction Cancer

NCT07429318
not_yet_recruitingphase_2

Primary Tumor Resection With Sintilimab and Chemotherapy in Advanced NSCLC

NCT07177105
not_yet_recruitingphase_2

A Study Evaluating Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade for Limited-stage Small Cell Lung Cancer

NCT07103408
recruiting

Prospective Cohort Study for Lymphoma: Samsung Lymphoma Cohort Study IV

NCT07032103
recruitingphase_2

Sintilimab, Pegaspargase Plus GemOx for Untreated Extranodal NK/T-Cell Lymphoma

NCT06824883
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT07429318

Efficacy and Survival Analysis of Perioperative Treatment of Locally Advanced Gastric or Gastroesophageal Junction Cancer

Active Not Recruiting
NCT07177105Phase 2

Primary Tumor Resection With Sintilimab and Chemotherapy in Advanced NSCLC

Not Yet Recruiting
NCT07103408Phase 2

A Study Evaluating Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade for Limited-stage Small Cell Lung Cancer

Not Yet Recruiting
NCT07032103

Prospective Cohort Study for Lymphoma: Samsung Lymphoma Cohort Study IV

Recruiting
NCT06824883Phase 2

Sintilimab, Pegaspargase Plus GemOx for Untreated Extranodal NK/T-Cell Lymphoma

Recruiting
NCT06671262Phase 2

Neoadjuvant Toripalimab and Radiotherapy Treatment in N+ HR+ Breast Cancer

Recruiting
NCT06475755Phase 2

Neoadjuvant/Adjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLC

Not Yet Recruiting
NCT06306846Phase 2

Neoadjuvant SBRT in Localized Advanced HNSCC

Recruiting
NCT01458730Phase 2

Nordic Study in Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma

Completed
NCT02782845Phase 4

An Expanded Access Program of Pegfilgrastim (Neulastim) in Participants With Non-Hodgkin's Lymphoma (NHL)

Completed
NCT00946374Phase 2

Prospective Trial on Immunochemotherapy Plus Autologous Stem Cell Transplantation (SCT) and Allogenic SCT in Primary Mantle-Cell-Lymphoma

Unknown

All 11 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
11